U.S., June 30 -- ClinicalTrials.gov registry received information related to the study (NCT07672782) titled 'Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva' on June 08.
Brief Summary: This is an open-label, single arm, phase 2 study designed to evaluate the efficacy of tisotumab vedotin in participants with recurrent or metastatic squamous cell carcinoma of the vulva by estimating the objective response rate.
Patients will receive tisotumab vedotin every 3 weeks (21 days plus or minus 3 days). Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.
Study Start Date: Nov., 2026
Study Type: INTERVENTIONAL
Condition:
Vulvar Carcinoma
Recurrent or Metas...